New study aims to find safer heart failure treatment for kidney patients
NCT ID NCT07523867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs, finerenone and spironolactone, in 60 adults with heart failure and diabetic kidney disease who are at high risk for high potassium levels (hyperkalemia). Participants will receive either finerenone daily or spironolactone every other day, plus standard care, and be monitored for 4 weeks. The goal is to see which drug is safer by tracking potassium levels and any need to stop or adjust treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Blood test may predict rapid kidney decline in diabetes
- Blood test could flag rapid kidney failure risk in diabetes
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?